Roots Analysis has done a detailed study on “Aseptic Fill Finish Market, 2023-2035”, covering key aspects of the industry and identifying future growth opportunities.

Key Market Insights

§  Over 175 companies claim to offer fill / finish services for various types of biopharmaceutical drug products; the growth initiatives, in this segment, are being led by large and mid-sized players

§  More than 70% of the service providers offer fill / finish for proteins and peptides; in addition, ~80% of the players have the required capabilities to carry out lyophilization operations

§  Around 125 industry players offer fill / finish services for various types of small molecule drug products, across different scales of operation

§  Leveraging their expertise, 85% stakeholders extend services for labelling and packaging, both for clinical and commercial scale operations

§  In order to expand their aseptic fill / finish service portfolios and gain access to emerging technologies, companies are actively entering into strategic partnerships

§  The aseptic fill finish market is likely to grow at a CAGR of ~11%, till 2035; this opportunity is expected to be well distributed across different types of molecules, packaging containers and drug products

§  In the long-term, the US (~30%) is likely to significantly contribute towards the market growth, followed by Asia-Pacific countries; specifically, within Europe, Germany and France are like to account for ~5% market share, each

Table of Contents

TABLE OF CONTENTS

1.         PREFACE

1.1.      Chapter Overview

1.2.      Key Insights

1.3.      Scope of the Report

1.4.      Research Methodology

1.5.      Frequently Asked Questions

1.6.      Chapter Outlines

2.         EXECUTIVE SUMMARY

3.         INTRODUCTION

3.1.      Chapter Overview

3.2.      Introduction to Contract Manufacturing 

3.3.      Commonly Outsourced Operations in Biopharmaceutical Industry

3.4.      Basic Guidelines for Selecting a Fill / Finish Service Provider

3.5.      Advantages of Outsourcing Fill / Finish Operations

3.6.      Risks and Challenges Associated with Outsourcing Fill / Finish Operations

3.7.      Concluding Remarks

4.         ASEPTIC FILL FINISH SERVICE PROVIDERS LANDSCAPE

4.1.      Chapter Overview

4.2.      Aseptic Fill / Finish: Service Providers Landscape

5.         BIOLOGICS FILL / FINISH SERVICE PROVIDERS LANDSCAPE

5.1.      Chapter Overview 

5.2.      Biologics Fill / Finish: Service Providers Landscape

6.         SMALL MOLECULE FILL / FINISH SERVICE PROVIDERS LANDSCAPE

6.1.      Chapter Overview

6.2.      Small Molecule Fill / Finish: Service Providers Landscape

7.         COMPANY PROFILES: ASEPTIC FILL / FINISH SERVICE PROVIDERS IN NORTH AMERICA

7.1.      Chapter Overview

7.2.      Companies Offering Aseptic Fill / Finish Services for Biologics

7.2.1.   AbbVie Contract Manufacturing

7.2.1.1.            Company Snapshot

7.2.1.2.            Financial Information

7.2.1.3.            Service Portfolio

7.2.1.4.            Fill / Finish Services Offered

7.2.1.5.            Recent Developments and Future Outlook

7.2.2.   BioPharma Solutions           

7.2.3.   BioReliance

7.2.4.   Catalent Biologics

7.2.5.   Charles River Laboratories

7.2.6.   Patheon

7.3.      Companies Offering Aseptic Fill / Finish Services for Small Molecules

7.3.1.1.            Pfizer CentreOne

7.3.1.2.            Company Snapshot

7.3.1.3.            Service Portfolio

7.3.1.4.            Fill / Finish Services Offered

7.3.1.5.            Recent Developments and Future Outlook

7.3.2.   Plastikon Healthcare

7.3.3.   Sharp Services

8.         COMPANY PROFILES: ASEPTIC FILL / FINISH SERVICE PROVIDERS IN EUROPE

8.1.      Company Overview

8.2.      Companies Offering Aseptic Fill / Finish Services for Biologics

8.2.1.   Boehringer Ingelheim BioXcellence

8.2.1.1. Company Snapshot

8.2.1.2.            Financial Information

8.2.1.3.            Service Portfolio

8.2.1.4.            Fill / Finish Services Offered

8.2.1.5. Recent Developments and Future Outlook

8.2.2.   Fareva

8.2.3.   GlaxoSmithKline      

8.2.4.   Lonza

8.2.5.   Pierre Fabre 

8.2.6.   Wacker Biotech

8.3.      Companies Offering Aseptic Fill / Finish Services for Small Molecules

8.3.1.   Aenova

8.3.2.   APL

8.3.3    CordenPharma

8.3.4.   Delpharm

8.3.5    PiSA Farmaceutica

8.4       Companies Offering Aseptic Fill / Finish Services for Biologics and Small Molecules

8.4.1    Fresenius Kabi

8.4.2    Recipharm

9.         COMPANY PROFILES: ASEPTIC FILL / FINISH SERVICE PROVIDERS IN ASIA-PACIFIC

9.1       Company Overview

9.2       Companies Offering Aseptic Fill / Finish Services for Biologics

9.2.1    Asymchem

9.2.2.   Samsung Biologics

9.2.3.   Syngene

9.2.4.   Takara Bio

9.2.5.   WuXi Biologics

9.2.6.   Hetero Drugs

9.2.7.   Intas Pharmaceuticals

9.3.      Companies Offering Aseptic Fill / Finish Services for Small Molecules

9.3.1.   Siegfried        

9.3.2.   Wockhardt

10.       PARTNERSHIPS AND COLLABORATIONS

10.1.    Chapter Overview

10.2.    Partnership Models

10.3.    Aseptic Fill / Finish Service Providers: List of Partnerships and Collaborations

11.       MARKET SIZING AND OPPORTUNITY ANALYSIS

11.1.    Chapter Overview

11.2.    Forecast Methodology

11.3.    Overall Aseptic Fill / Finish Services Market, 2023-2035

11.4.    Aseptic Fill / Finish Services Market for Biologics, 2023-2035

11.5.    Aseptic Fill / Finish Services Market for Small Molecules, 2023-2035

12.       CASE STUDY: ROBOTICS IN PHARMACEUTICAL PACKAGING

12.1.    Chapter Overview

12.2.    Role of Robotic Systems in Pharmaceutical Industry

12.3.    Role of Robotic Systems in Fill / Finish Operation

12.4.    Contract Service Providers: List of Fill / Finish Equipment

12.5.    Companies Providing Robots for Use in the Pharmaceutical Industry

12.6.    Companies Providing Isolator based Aseptic Filling Systems

12.7.    Concluding Remarks

13.       CASE STUDY: READY-TO-USE PACKAGING COMPONENTS FOR ASEPTIC FILL / FINISH

13.1.    Chapter Overview

13.2.    Role of Ready-to-Use Packaging Components in Aseptic Fill / Finish Operations

13.3.    Companies Providing Ready-to-Use Packaging Components

13.4.    Concluding Remarks

14.       CONCLUDING REMARKS

15.       EXECUTIVE INSIGHTS

15.1     Chapter Overview

15.2     IDT Biologika

15.3     Cytovance Biologics

15.4.    Syngene

15.5     oncomed manufacturing

15.6     Yposkesi

15.7     HALIX

16.       APPENDIX 1: TABULATED DATA

17.       APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

To view mo